Incyte (INCY) — insider trading
Health Care · NASDAQ
Incyte (INCY) has 162 reported SEC Form 4 insider transactions in our data, including 21 open-market sales among the most recent 100 (latest 2026-10-01).
Recent Form 4 transactions
Showing the 100 most recent of 162 recorded transactions. See all on SEC EDGAR →
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | Heeson Lee | Officer (EVP, Head of Incyte Intl) | Shares withheld for taxes / exercise cost | 463 | $117.14 | $54.2K | Form 4 |
| 2026-09-30 | HARRIGAN EDMUND | Director | Grant / award / vesting | 206 | $121.35 | $25.0K | Form 4 |
| 2026-09-30 | Clancy Paul J | Director | Grant / award / vesting | 203 | $121.35 | $24.6K | Form 4 |
| 2026-09-30 | BAKER BROS. ADVISORS LP; 667, L.P.; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP; BAKER FELIX; BAKER JULIAN | Director, 10% owner | Grant / award / vesting | 322 | — | $0 | Form 4 |
| 2026-09-30 | BAKER BROS. ADVISORS LP; 667, L.P.; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP; BAKER FELIX; BAKER JULIAN | Director, 10% owner | Grant / award / vesting | 322 | — | $0 | Form 4 |
| 2026-09-22 | Gardner David H | Officer (EVP, Chief Strategy Officer) | Shares withheld for taxes / exercise cost | 920 | $126.93 | $116.8K | Form 4 |
| 2026-09-15 | CAGNONI PABLO J | Officer (President, Global Head of R&D) | Option exercise / conversion (derivative) | 9,233 | — | $0 | Form 4 |
| 2026-09-15 | CAGNONI PABLO J | Officer (President, Global Head of R&D) | Option exercise / conversion (derivative) | 6,477 | — | $0 | Form 4 |
| 2026-09-15 | CAGNONI PABLO J | Officer (President, Global Head of R&D) | Option exercise / conversion (derivative) | 4,551 | — | $0 | Form 4 |
| 2026-09-15 | CAGNONI PABLO J | Officer (President, Global Head of R&D) | Option exercise / conversion (derivative) | 2,957 | — | $0 | Form 4 |
| 2026-09-15 | CAGNONI PABLO J | Officer (President, Global Head of R&D) | Open-market sale | 13,985 | $120.49 | $1.69M | Form 4 |
| 2026-09-15 | CAGNONI PABLO J | Officer (President, Global Head of R&D) | Open-market sale | 9,233 | $120.50 | $1.11M | Form 4 |
| 2026-09-15 | CAGNONI PABLO J | Officer (President, Global Head of R&D) | Option exercise / conversion | 9,233 | $71.93 | $664.1K | Form 4 |
| 2026-09-15 | CAGNONI PABLO J | Officer (President, Global Head of R&D) | Option exercise / conversion | 6,477 | $64.25 | $416.1K | Form 4 |
| 2026-09-15 | CAGNONI PABLO J | Officer (President, Global Head of R&D) | Option exercise / conversion | 4,551 | $61.18 | $278.4K | Form 4 |
| 2026-09-15 | CAGNONI PABLO J | Officer (President, Global Head of R&D) | Option exercise / conversion | 2,957 | $61.76 | $182.6K | Form 4 |
| 2026-08-25 | Basi Ramitpal K | Officer (EVP, Human Resources) | Shares withheld for taxes / exercise cost | 504 | $129.72 | $65.4K | Form 4 |
| 2026-08-19 | CAGNONI PABLO J | Officer (President, Global Head of R&D) | Open-market sale | 10,801 | $125.56 | $1.36M | Form 4 |
| 2026-08-12 | CAGNONI PABLO J | Officer (President, Global Head of R&D) | Open-market sale | 10,803 | $120.04 | $1.30M | Form 4 |
| 2026-08-05 | Mayes Patrick A | Officer (EVP & Chief Scientific Officer) | Option exercise / conversion (derivative) | 2,207 | — | $0 | Form 4 |
| 2026-08-05 | Mayes Patrick A | Officer (EVP & Chief Scientific Officer) | Open-market sale | 2,207 | $123.99 | $273.6K | Form 4 |
| 2026-08-05 | Mayes Patrick A | Officer (EVP & Chief Scientific Officer) | Option exercise / conversion | 2,207 | $106.47 | $235.0K | Form 4 |
| 2026-08-05 | CAGNONI PABLO J | Officer (President, Global Head of R&D) | Open-market sale | 10,640 | $122.69 | $1.31M | Form 4 |
| 2026-08-03 | Mayes Patrick A | Officer (EVP & Chief Scientific Officer) | Option exercise / conversion (derivative) | 6,055 | — | $0 | Form 4 |
| 2026-08-03 | Mayes Patrick A | Officer (EVP & Chief Scientific Officer) | Open-market sale | 6,055 | $120.43 | $729.2K | Form 4 |
| 2026-08-03 | Mayes Patrick A | Officer (EVP & Chief Scientific Officer) | Option exercise / conversion | 6,055 | $105.43 | $638.4K | Form 4 |
| 2026-07-31 | Mayes Patrick A | Officer (EVP & Chief Scientific Officer) | Option exercise / conversion (derivative) | 326 | — | $0 | Form 4 |
| 2026-07-31 | Mayes Patrick A | Officer (EVP & Chief Scientific Officer) | Option exercise / conversion (derivative) | 85 | — | $0 | Form 4 |
| 2026-07-31 | Mayes Patrick A | Officer (EVP & Chief Scientific Officer) | Option exercise / conversion (derivative) | 2,293 | — | $0 | Form 4 |
| 2026-07-31 | Mayes Patrick A | Officer (EVP & Chief Scientific Officer) | Option exercise / conversion (derivative) | 1,642 | — | $0 | Form 4 |
| 2026-07-31 | Mayes Patrick A | Officer (EVP & Chief Scientific Officer) | Option exercise / conversion (derivative) | 2,623 | — | $0 | Form 4 |
| 2026-07-31 | Mayes Patrick A | Officer (EVP & Chief Scientific Officer) | Option exercise / conversion (derivative) | 3,023 | — | $0 | Form 4 |
| 2026-07-31 | Mayes Patrick A | Officer (EVP & Chief Scientific Officer) | Option exercise / conversion (derivative) | 1,643 | — | $0 | Form 4 |
| 2026-07-31 | Mayes Patrick A | Officer (EVP & Chief Scientific Officer) | Option exercise / conversion (derivative) | 2,864 | — | $0 | Form 4 |
| 2026-07-31 | Mayes Patrick A | Officer (EVP & Chief Scientific Officer) | Option exercise / conversion (derivative) | 2,623 | — | $0 | Form 4 |
| 2026-07-31 | Mayes Patrick A | Officer (EVP & Chief Scientific Officer) | Option exercise / conversion (derivative) | 9,459 | — | $0 | Form 4 |
| 2026-07-31 | Mayes Patrick A | Officer (EVP & Chief Scientific Officer) | Option exercise / conversion (derivative) | 2,072 | — | $0 | Form 4 |
| 2026-07-31 | Mayes Patrick A | Officer (EVP & Chief Scientific Officer) | Option exercise / conversion (derivative) | 3,148 | — | $0 | Form 4 |
| 2026-07-31 | Mayes Patrick A | Officer (EVP & Chief Scientific Officer) | Option exercise / conversion (derivative) | 2,709 | — | $0 | Form 4 |
| 2026-07-31 | Mayes Patrick A | Officer (EVP & Chief Scientific Officer) | Option exercise / conversion (derivative) | 2,284 | — | $0 | Form 4 |
| 2026-07-31 | Mayes Patrick A | Officer (EVP & Chief Scientific Officer) | Option exercise / conversion (derivative) | 2,918 | — | $0 | Form 4 |
| 2026-07-31 | Mayes Patrick A | Officer (EVP & Chief Scientific Officer) | Open-market sale | 2,293 | $119.41 | $273.8K | Form 4 |
| 2026-07-31 | Mayes Patrick A | Officer (EVP & Chief Scientific Officer) | Open-market sale | 326 | $121.69 | $39.7K | Form 4 |
| 2026-07-31 | Mayes Patrick A | Officer (EVP & Chief Scientific Officer) | Open-market sale | 85 | $122.19 | $10.4K | Form 4 |
| 2026-07-31 | Mayes Patrick A | Officer (EVP & Chief Scientific Officer) | Open-market sale | 1,642 | $119.38 | $196.0K | Form 4 |
| 2026-07-31 | Mayes Patrick A | Officer (EVP & Chief Scientific Officer) | Open-market sale | 1,643 | $119.51 | $196.4K | Form 4 |
| 2026-07-31 | Mayes Patrick A | Officer (EVP & Chief Scientific Officer) | Open-market sale | 2,864 | $119.40 | $342.0K | Form 4 |
| 2026-07-31 | Mayes Patrick A | Officer (EVP & Chief Scientific Officer) | Open-market sale | 4,695 | $119.39 | $560.5K | Form 4 |
| 2026-07-31 | Mayes Patrick A | Officer (EVP & Chief Scientific Officer) | Open-market sale | 6,171 | $119.43 | $737.0K | Form 4 |
| 2026-07-31 | Mayes Patrick A | Officer (EVP & Chief Scientific Officer) | Open-market sale | 2,187 | $119.47 | $261.3K | Form 4 |
| 2026-07-31 | Mayes Patrick A | Officer (EVP & Chief Scientific Officer) | Open-market sale | 5,332 | $119.42 | $636.7K | Form 4 |
| 2026-07-31 | Mayes Patrick A | Officer (EVP & Chief Scientific Officer) | Open-market sale | 14,661 | $119.46 | $1.75M | Form 4 |
| 2026-07-31 | Mayes Patrick A | Officer (EVP & Chief Scientific Officer) | Option exercise / conversion | 326 | $105.43 | $34.4K | Form 4 |
| 2026-07-31 | Mayes Patrick A | Officer (EVP & Chief Scientific Officer) | Option exercise / conversion | 85 | $106.47 | $9.0K | Form 4 |
| 2026-07-31 | Mayes Patrick A | Officer (EVP & Chief Scientific Officer) | Option exercise / conversion | 2,293 | $90.56 | $207.7K | Form 4 |
| 2026-07-31 | Mayes Patrick A | Officer (EVP & Chief Scientific Officer) | Option exercise / conversion | 1,642 | $85.01 | $139.6K | Form 4 |
| 2026-07-31 | Mayes Patrick A | Officer (EVP & Chief Scientific Officer) | Option exercise / conversion | 2,623 | $83.58 | $219.2K | Form 4 |
| 2026-07-31 | Mayes Patrick A | Officer (EVP & Chief Scientific Officer) | Option exercise / conversion | 3,023 | $83.20 | $251.5K | Form 4 |
| 2026-07-31 | Mayes Patrick A | Officer (EVP & Chief Scientific Officer) | Option exercise / conversion | 1,643 | $80.50 | $132.3K | Form 4 |
| 2026-07-31 | Mayes Patrick A | Officer (EVP & Chief Scientific Officer) | Option exercise / conversion | 2,864 | $77.67 | $222.4K | Form 4 |
| 2026-07-31 | Mayes Patrick A | Officer (EVP & Chief Scientific Officer) | Option exercise / conversion | 2,623 | $74.78 | $196.1K | Form 4 |
| 2026-07-31 | Mayes Patrick A | Officer (EVP & Chief Scientific Officer) | Option exercise / conversion | 9,459 | $72.27 | $683.6K | Form 4 |
| 2026-07-31 | Mayes Patrick A | Officer (EVP & Chief Scientific Officer) | Option exercise / conversion | 2,072 | $71.93 | $149.0K | Form 4 |
| 2026-07-31 | Mayes Patrick A | Officer (EVP & Chief Scientific Officer) | Option exercise / conversion | 3,148 | $68.62 | $216.0K | Form 4 |
| 2026-07-31 | Mayes Patrick A | Officer (EVP & Chief Scientific Officer) | Option exercise / conversion | 2,709 | $61.76 | $167.3K | Form 4 |
| 2026-07-31 | Mayes Patrick A | Officer (EVP & Chief Scientific Officer) | Option exercise / conversion | 2,284 | $64.25 | $146.7K | Form 4 |
| 2026-07-31 | Mayes Patrick A | Officer (EVP & Chief Scientific Officer) | Option exercise / conversion | 2,918 | $61.18 | $178.5K | Form 4 |
| 2026-07-31 | CAGNONI PABLO J | Officer (President, Global Head of R&D) | Open-market sale | 15,888 | $119.70 | $1.90M | Form 4 |
| 2026-07-23 | Heeson Lee | Officer (EVP, Head of Incyte Intl) | Grant / award / vesting (derivative) | 13,498 | — | $0 | Form 4 |
| 2026-07-23 | Heeson Lee | Officer (EVP, Head of Incyte Intl) | Grant / award / vesting (derivative) | 15,423 | — | $0 | Form 4 |
| 2026-07-23 | Morrissey Michael James | Officer (EVP, Head of Tech. Operations) | Grant / award / vesting (derivative) | 8,999 | — | $0 | Form 4 |
| 2026-07-23 | Morrissey Michael James | Officer (EVP, Head of Tech. Operations) | Grant / award / vesting (derivative) | 6,426 | — | $0 | Form 4 |
| 2026-07-16 | Meury William | Director, Officer (Chief Executive Officer) | Grant / award / vesting (derivative) | 77,148 | — | $0 | Form 4 |
| 2026-07-16 | Meury William | Director, Officer (Chief Executive Officer) | Grant / award / vesting (derivative) | 80,421 | — | $0 | Form 4 |
| 2026-07-16 | Meury William | Director, Officer (Chief Executive Officer) | Grant / award / vesting | 26,807 | — | $0 | Form 4 |
| 2026-07-16 | Hoffman Richard A. | Officer (EVP & General Counsel) | Grant / award / vesting (derivative) | 31,923 | — | $0 | Form 4 |
| 2026-07-16 | Hoffman Richard A. | Officer (EVP & General Counsel) | Grant / award / vesting (derivative) | 18,487 | — | $0 | Form 4 |
| 2026-07-16 | Hoffman Richard A. | Officer (EVP & General Counsel) | Grant / award / vesting | 7,395 | — | $0 | Form 4 |
| 2026-07-16 | Gardner David H | Officer (EVP, Chief Strategy Officer) | Grant / award / vesting (derivative) | 31,923 | — | $0 | Form 4 |
| 2026-07-16 | Gardner David H | Officer (EVP, Chief Strategy Officer) | Grant / award / vesting (derivative) | 18,487 | — | $0 | Form 4 |
| 2026-07-16 | Gardner David H | Officer (EVP, Chief Strategy Officer) | Grant / award / vesting | 7,395 | — | $0 | Form 4 |
| 2026-07-16 | Basi Ramitpal K | Officer (EVP, Human Resources) | Grant / award / vesting (derivative) | 21,548 | — | $0 | Form 4 |
| 2026-07-16 | Basi Ramitpal K | Officer (EVP, Human Resources) | Grant / award / vesting (derivative) | 12,479 | — | $0 | Form 4 |
| 2026-07-16 | Basi Ramitpal K | Officer (EVP, Human Resources) | Grant / award / vesting | 4,991 | — | $0 | Form 4 |
| 2026-07-16 | Issa Mohamed Khairie | Officer (EVP, Head of U.S. Commercial) | Grant / award / vesting (derivative) | 33,918 | — | $0 | Form 4 |
| 2026-07-16 | Issa Mohamed Khairie | Officer (EVP, Head of U.S. Commercial) | Grant / award / vesting (derivative) | 19,643 | — | $0 | Form 4 |
| 2026-07-16 | Issa Mohamed Khairie | Officer (EVP, Head of U.S. Commercial) | Grant / award / vesting | 7,857 | — | $0 | Form 4 |
| 2026-07-16 | Issa Mohamed Khairie | Officer (EVP, Head of U.S. Commercial) | Open-market sale | 1,093 | $115.01 | $125.7K | Form 4 |
| 2026-07-16 | CAGNONI PABLO J | Officer (President, Global Head of R&D) | Grant / award / vesting (derivative) | 57,861 | — | $0 | Form 4 |
| 2026-07-16 | CAGNONI PABLO J | Officer (President, Global Head of R&D) | Grant / award / vesting (derivative) | 33,508 | — | $0 | Form 4 |
| 2026-07-16 | CAGNONI PABLO J | Officer (President, Global Head of R&D) | Grant / award / vesting | 13,403 | — | $0 | Form 4 |
| 2026-07-16 | Mayes Patrick A | Officer (EVP & Chief Scientific Officer) | Grant / award / vesting (derivative) | 25,538 | — | $0 | Form 4 |
| 2026-07-16 | Mayes Patrick A | Officer (EVP & Chief Scientific Officer) | Grant / award / vesting (derivative) | 14,790 | — | $0 | Form 4 |
| 2026-07-16 | Mayes Patrick A | Officer (EVP & Chief Scientific Officer) | Grant / award / vesting | 5,916 | — | $0 | Form 4 |
| 2026-07-16 | Stein Steven H | Officer (CMO & Head of Late-Stage Dev.) | Grant / award / vesting (derivative) | 42,298 | — | $0 | Form 4 |
| 2026-07-16 | Stein Steven H | Officer (CMO & Head of Late-Stage Dev.) | Grant / award / vesting (derivative) | 24,496 | — | $0 | Form 4 |
| 2026-07-16 | Stein Steven H | Officer (CMO & Head of Late-Stage Dev.) | Grant / award / vesting | 9,798 | — | $0 | Form 4 |
| 2026-07-16 | Stein Steven H | Officer (CMO & Head of Late-Stage Dev.) | Open-market sale | 1,877 | $114.73 | $215.3K | Form 4 |
| 2026-07-16 | Tray Thomas | Officer (Principal Accounting Officer) | Grant / award / vesting (derivative) | 4,079 | — | $0 | Form 4 |
| 2026-07-16 | Tray Thomas | Officer (Principal Accounting Officer) | Grant / award / vesting | 2,834 | — | $0 | Form 4 |
Ask the chat about INCY's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: Incyte (INCY).
Last updated 2026-10-01 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.